microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus.

Early-life stress is a main contributory factor to the onset of depression. Treatments remain inadequate and as such, a large unmet medical need for novel therapeutics remains. Impeding advancement is the poor understanding of the molecular pathology. microRNAs (miRNAs) are novel regulators of gene expression. A paucity of information regarding their role in depressive pathology and antidepressant action remains. This study investigated changes to hippocampal miRNA levels induced via early-life stress in Sprague-Dawley rats and whether antidepressant treatments could reverse these changes. Investigated were the selective serotonin reuptake inhibitor fluoxetine, the rapid acting N-methyl-d-aspartate receptor antagonist ketamine and electroconvulsive shock therapy (ECT). Microarray analysis revealed early-life stress affected the expression of multiple hippocampal miRNAs. Antidepressant treatments reversed some of these effects including a stress-induced change to miR-451. Ketamine and ECT possessed the highest number of common targets suggesting convergence on common pathways. Interestingly all three treatments possessed miR-598-5p as a common target. This demonstrates that changes to hippocampal miRNA expression may represent an important component of stress-induced pathology and antidepressant action may reverse these.

[1]  T. Dinan,et al.  Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: Effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment , 2013, Neuropharmacology.

[2]  J. Schreiber,et al.  MiR-133b Targets Antiapoptotic Genes and Enhances Death Receptor-Induced Apoptosis , 2012, PloS one.

[3]  T. Dinan,et al.  Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression , 2012, Molecular Psychiatry.

[4]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[5]  L. Desbonnet,et al.  Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression , 2010, Neuroscience.

[6]  B. McEwen,et al.  Early Life Stress Enhances Behavioral Vulnerability to Stress through the Activation of REST4-Mediated Gene Transcription in the Medial Prefrontal Cortex of Rodents , 2010, The Journal of Neuroscience.

[7]  J. Launay,et al.  MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants , 2010, Science.

[8]  C. Zarate,et al.  Glutamatergic modulators: the future of treating mood disorders? , 2010, Harvard review of psychiatry.

[9]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[10]  T. Dinan,et al.  Riluzole normalizes early-life stress-induced visceral hypersensitivity in rats: role of spinal glutamate reuptake mechanisms. , 2010, Gastroenterology.

[11]  E. Nestler,et al.  From synapse to nucleus: Novel targets for treating depression , 2010, Neuropharmacology.

[12]  T. Dinan,et al.  5‐HT2B receptors modulate visceral hypersensitivity in a stress‐sensitive animal model of brain‐gut axis dysfunction , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[13]  D. Kaufer,et al.  Mechanisms , 2009, Superconducting State.

[14]  Brian D Athey,et al.  New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. , 2009, Genome research.

[15]  Guang Chen,et al.  Evidence for Selective microRNAs and Their Effectors as Common Long-Term Targets for the Actions of Mood Stabilizers , 2009, Neuropsychopharmacology.

[16]  T. Dinan,et al.  Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[17]  R. Kessler,et al.  The descriptive epidemiology of commonly occurring mental disorders in the United States. , 2008, Annual review of public health.

[18]  J. Ballenger.  A Randomized Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Major DepressionZarate CA, Singh JB, Carlson PJ, et al (NIH, Bethesda, Md) Arch Gen Psychiatry 63:856–864, 2006§ , 2008 .

[19]  Eric J. Nestler,et al.  Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.

[20]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[21]  R. Duman,et al.  TNFα Signaling in Depression and Anxiety: Behavioral Consequences of Individual Receptor Targeting , 2006, Biological Psychiatry.

[22]  C. Beverley,et al.  Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. , 2005, Health technology assessment.

[23]  P Barton,et al.  Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. , 2005, Health technology assessment.

[24]  I. Lucki,et al.  Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Manji,et al.  Life Stress, Genes, and Depression: Multiple Pathways Lead to Increased Risk and New Opportunities for Intervention , 2004, Science's STKE.

[26]  Julio Licinio,et al.  From monoamines to genomic targets: a paradigm shift for drug discovery in depression , 2004, Nature Reviews Drug Discovery.

[27]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[28]  H. Manji,et al.  Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression , 2003, Biological Psychiatry.

[29]  R. Duman,et al.  ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment , 2001, The journal of ECT.

[30]  M. Meaney,et al.  Variations in maternal care in infancy regulate the development of stress reactivity , 2000, Biological Psychiatry.

[31]  I. Lucki,et al.  Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[32]  D. Hedeker,et al.  Rearing experience and biogenic amine activity in infant rhesus monkeys , 1996, Biological Psychiatry.